Product Center
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully held
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-02-18
- Views:
(Summary description)Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully held
(Summary description)Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-02-18 11:39
- Views:
Recently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed.
Herpes zoster (HZ) is caused by the varicella-zoster virus (VZV). Primary infection with this virus initially leads to chickenpox, after which the virus migrates from skin lesions and becomes latent in cranial ganglia, dorsal root ganglia, and autonomic ganglia along the neural axis. As people age or when their body's resistance decreases due to certain stimuli, VZV can be reactivated and cause herpes zoster. The general population is susceptible to VZV. Serological evidence shows that the VZV infection rate in adults is as high as over 90%, so the population is generally likely to develop herpes zoster. Herpes zoster can occur at any age, but its incidence rises significantly with increasing age. Herpes zoster not only affects the physical and mental health of patients, leading to a decline in their quality of life, but also imposes a significant disease burden and public health problem on families and society.
Our company has independently developed a recombinant herpes zoster vaccine (CHO cells), which incorporates a patented gE protein sequence, retains the advantageous antigenic epitopes, and innovatively employs a dual adjuvant system. This vaccine can effectively stimulate a specific immune response against VZV. Pre-clinical study data demonstrate that this vaccine induces stronger cell-mediated immune responses in animal models, suggesting potentially enhanced immunogenicity. Additionally, its high expression level of antigenic proteins may help reduce industrial production costs. If successfully approved for market, this vaccine will significantly improve the current supply of herpes zoster vaccines, offering the public a cost-effective vaccination option while strengthening our company’s competitive edge in the vaccine sector.
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
